Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 327

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study

Open access
Fernandez, Hubert H., Factor, Stewart A., Hauser, Robert A., Jimenez-Shahed, Joohi, Ondo, William G., Jarskog, L. Fredrik, Meltzer, Herbert Y., Woods, Scott W., Bega, Danny, LeDoux, Mark S., Shprecher, David R., Davis, Charles, Davis, Mat D., Stamler, David, Anderson, Karen E. · 2017 · Neurology

Abstract

OBJECTIVE: To determine the efficacy and safety of deutetrabenazine as a treatment for tardive dyskinesia (TD). METHODS: One hundred seventeen patients with moderate to severe TD received deutetrabenazine or placebo in this randomized, double-blind, multicenter trial. Eligibility criteria included an Abnormal Involuntary Movement Scale (AIMS) score of ≥6 assessed by blinded central video rating, stable psychiatric illness, and stable psychoactive medication treatment. Primary endpoint was the change in AIMS score from baseline to week 12. Secondary endpoints included treatment success at week 12 on the Clinical Global Impression of Change (CGIC) and Patient Global Impression of Change. RESULTS: = 0.019). Treatment success on CGIC (48.2% vs 40.4%) favored deutetrabenazine but was not significant. Deutetrabenazine and placebo groups showed low rates of psychiatric adverse events: anxiety (3.4% vs 6.8%), depressed mood/depression (1.7% vs 1.7%), and suicidal ideation (0% vs 1.7%, respectively). In addition, no worsening in parkinsonism, as measured by the Unified Parkinson's Disease Rating Scale motor subscale, was noted from baseline to week 12 in either group. CONCLUSIONS: In patients with TD, deutetrabenazine was well tolerated and significantly reduced abnormal movements. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that in patients with TD, deutetrabenazine reduces AIMS scores.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000003960

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 327

Metadata

Authors
Fernandez, H. H., Factor, S. A., Hauser, R. A., Jimenez-Shahed, J., Ondo, W. G., Jarskog, L. F., Meltzer, H. Y., Woods, S. W., Bega, D., LeDoux, M. S., Shprecher, D. R., Davis, C., Davis, M. D., Stamler, D., & Anderson, K. E.
Venue
Neurology
Published
2017-05-23
Volume
88
Issue
21
Pages
2003-2010
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2609324068
Cited by
327
References
20
FWCI
49.02
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. https://app.cochat.ai/papers/10.1212/wnl.0000000000003960
The paper
Fernandez, H. H., Factor, S. A., Hauser, R. A., Jimenez-Shahed, J., Ondo, W. G., Jarskog, L. F., Meltzer, H. Y., Woods, S. W., Bega, D., LeDoux, M. S., Shprecher, D. R., Davis, C., Davis, M. D., Stamler, D., & Anderson, K. E. (2017). Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology. https://doi.org/10.1212/wnl.0000000000003960

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.